Zawiadomienie o rozstrzygnięciu postępowania
Zamawiający BioVentures Institute Sp. z o.o informuje, że w wyniku przeprowadzonego postępowania na usługę: Opracowanie technologii...
top of page
Recent news
Archived news
- Jul 11
ZAPYTANIE OFERTOWE
BioVentures Institute Sp. z o.o, jako podmiot realizujący projekt współfinansowany z Europejskiego Funduszu Rozwoju Regionalnego na...
- Jun 3
New publication in Critical Reviews in Microbiology
This publication is a result of long-term scientific cooperation and partnership between BioVentures Institute, University of Gdańsk,...
- Aug 2, 2022
New publication in Microorganisms
This publication is a result of long-term scientific cooperation and partnership between BioVentures Institute, University of Gdańsk,...
- Jan 28, 2022
New Publication in Microbial Cell Factories
This publication is a result of long-term scientific cooperation and partnership between BioVentures Institute, University of Gdańsk,...
- Oct 1, 2021
Grant from The National Centre for Research and Development
The National Centre for Research and Development grant TECHMATSTRATEG2/410747/11/NCBR/2019 (2019-2022) to the Consortium led by...
- Jul 1, 2021
Bacteriophages of Thermophilic ‘Bacillus Group’Bacteria—A Review
The publication reviewing potential and used by BioVentures Institute thermophilic bacteriophages and Virus-Like-Particles (VLPs)...
- Jun 20, 2021
Positive initial animal trials of the recombinant anti-SARS-CoV-2 vaccine
The vaccine has been purified, analysed using a number of techniques, including electrophoresis, LC-MS, Western blotting and was...
- Apr 1, 2021
Development of a novel type of recombinant anti-SARS-CoV-2 vaccine
The DNA-FACE™ concept of construction of ‘artificial’, concatemeric protein with a vaccine functionality has been used to construct an...
- Mar 9, 2021
Patent in Israel granted for DNA-FACE™
Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
- Dec 31, 2020
Patent in US granted for DNA-FACE™
Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
- Nov 2, 2020
Funds from The National Centre for Research and Development
The National Centre for Research and Development grant TECHMATSTRATEG-III/0042/2019 (2020-2023) received by the Institute...
- Aug 27, 2020
Patent for EU
Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
- Aug 20, 2020
New publication in MethodsX international journal
Detailed laboratory protocols, concerning the patented BioVentures Institute genetic engineering and protein functional programming,...
- Aug 5, 2020
Patent for China
We have been informed by Chineese Patent Office that our patent application no 201580028495.1, concerning our break-through recombinant...
- Jul 1, 2020
Patent in US granted for DNA-FACE™
Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
- Jun 23, 2020
Scientific publication
Scientific publication in the area of industrial enzymes. A novel proteinase Onygena, an improved alternative to the ‘workhorse’ of...
- May 28, 2020
Patent for Israel
We have been informed by Israeli Patent Office that our patent application no 248011, concerning our break-through recombinant DNA...
- Apr 16, 2020
Patent for Japan
Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and...
- Mar 20, 2020
Patent application for India
We have been informed by Indian Patent Office that our patent application no 201647039411, concerning our break-through recombinant DNA...
bottom of page